124 related articles for article (PubMed ID: 8483844)
1. Comparison of the pharmacokinetics and pharmacodynamics of the aldose reductase inhibitors, AL03152 (RS), AL03802 (R), and AL03803 (S).
Park YH; Mayer PR; Barker R; DuPriest M; Griffin BW; Williams GW; York BM; Slattery JT
Pharm Res; 1993 Apr; 10(4):593-7. PubMed ID: 8483844
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and efficacy of structurally related spirohydantoin and spirosuccinimide aldose reductase inhibitors.
Park YH; Barker R; Griffin B; Barratt D; DuPriest M; Brazzell K; York B; Mayer P
Xenobiotica; 1992 May; 22(5):543-50. PubMed ID: 1413869
[TBL] [Abstract][Full Text] [Related]
3. Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats.
Griffin BW; McNatt LG; Chandler ML; York BM
Metabolism; 1987 May; 36(5):486-90. PubMed ID: 3106757
[TBL] [Abstract][Full Text] [Related]
4. Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors.
Brazzell RK; Park YH; Wooldridge CB; McCue B; Barker R; Couch R; York B
Drug Metab Dispos; 1990; 18(4):435-40. PubMed ID: 1976064
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of aldehyde reductase by aldose reductase inhibitors.
Sato S; Kador PF
Biochem Pharmacol; 1990 Sep; 40(5):1033-42. PubMed ID: 2117925
[TBL] [Abstract][Full Text] [Related]
6. Saturable tissue binding and imirestat pharmacokinetics in rats.
Chien JY; Banfield CR; Brazzell RK; Mayer PR; Slattery JT
Pharm Res; 1992 Apr; 9(4):469-73. PubMed ID: 1495891
[TBL] [Abstract][Full Text] [Related]
7. Relative importance of aldose reductase versus nonenzymatic glycosylation on sugar cataract formation in diabetic rats.
Kador PF; Lee JW; Fujisawa S; Blessing K; Lou MF
J Ocul Pharmacol Ther; 2000 Apr; 16(2):149-60. PubMed ID: 10803425
[TBL] [Abstract][Full Text] [Related]
8. Disposition of the aldose reductase inhibitor AL01576 in rats.
Park YH; Wooldridge CB; Mattern J; Stoltz ML; Brazzell RK
J Pharm Sci; 1988 Feb; 77(2):110-5. PubMed ID: 3129545
[TBL] [Abstract][Full Text] [Related]
9. Rat kidney aldose reductase and aldehyde reductase and polyol production in rat kidney.
Sato S
Am J Physiol; 1992 Nov; 263(5 Pt 2):F799-805. PubMed ID: 1443170
[TBL] [Abstract][Full Text] [Related]
10. AL-1576, an aldose reductase inhibitor (ARI), did not prevent the decrease of norepinephrine turnover in diabetic rats.
Yen TT; Fuller RW; Broderick CL; Hemrick-Luecke SK; Perry KW
Res Commun Chem Pathol Pharmacol; 1988 Aug; 61(2):257-60. PubMed ID: 3141993
[TBL] [Abstract][Full Text] [Related]
11. The prevention of biochemical changes in lens, retina, and nerve of galactosemic dogs by the aldose reductase inhibitor AL01576.
Lou MF; Dickerson JE; Chandler ML; Brazzell RK; York BM
J Ocul Pharmacol; 1989; 5(3):233-40. PubMed ID: 2516529
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent pharmacokinetics of the aldose reductase inhibitor imirestat in man.
Brazzell RK; Mayer PR; Dobbs R; McNamara PJ; Teng RL; Slattery JT
Pharm Res; 1991 Jan; 8(1):112-8. PubMed ID: 1901647
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of the aldose reductase inhibitor imirestat following topical ocular administration.
Brazzell RK; Wooldridge CB; Hackett RB; McCue BA
Pharm Res; 1990 Feb; 7(2):192-8. PubMed ID: 2106677
[TBL] [Abstract][Full Text] [Related]
14. Spiro hydantoin aldose reductase inhibitors derived from 8-aza-4-chromanones.
Sarges R; Goldstein SW; Welch WM; Swindell AC; Siegel TW; Beyer TA
J Med Chem; 1990 Jul; 33(7):1859-65. PubMed ID: 2113948
[TBL] [Abstract][Full Text] [Related]
15. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors.
Tilton RG; Chang K; Pugliese G; Eades DM; Province MA; Sherman WR; Kilo C; Williamson JR
Diabetes; 1989 Oct; 38(10):1258-70. PubMed ID: 2507378
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and aldose reductase inhibitory activity of 2-substituted-6-fluoro-2,3-dihydrospiro [4H-1-benzopyran-4, 4'-imidazolidine]-2',5'-diones.
Yamaguchi T; Miura K; Usui T; Unno R; Matsumoto Y; Fukushima M; Mizuno K; Kondo Y; Baba Y; Kurono M
Arzneimittelforschung; 1994 Mar; 44(3):344-8. PubMed ID: 8192700
[TBL] [Abstract][Full Text] [Related]
17. Oxidation of aldose reductase inhibitors ALO-4114 and ALO-3152 catalyzed by liver microsomes.
Kiss AD; Haggard K; Veltman JC; Ziegler DM
Drug Metab Dispos; 1992; 20(6):948-53. PubMed ID: 1362951
[TBL] [Abstract][Full Text] [Related]
18. Capillary gas chromatographic-electron-capture assay for the aldose reductase inhibitor imirestat in lens and plasma.
McCue BA; Park YH; Brazzell RK; Boltralik JJ
J Chromatogr; 1991 Apr; 565(1-2):255-64. PubMed ID: 1908477
[TBL] [Abstract][Full Text] [Related]
19. Studies on the biochemical effects of the aldose reductase inhibitor 2,7-difluorospirofluorene-9,5'-imidazolidine-2',4'-dione (Al 1576, HOE 843). Detection of D-glucaric and D-glucuronic acid excretion by high resolution 1H and 13C NMR spectroscopy.
Hoyle VR; Gilbert PJ; Troke JA; Vose CW; Nicholson JK
Biochem Pharmacol; 1992 Jul; 44(2):231-41. PubMed ID: 1642638
[TBL] [Abstract][Full Text] [Related]
20. Isoflavonoids from the rhizomes of Belamcanda chinensis and their effects on aldose reductase and sorbitol accumulation in streptozotocin induced diabetic rat tissues.
Jung SH; Lee YS; Lee S; Lim SS; Kim YS; Shin KH
Arch Pharm Res; 2002 Jun; 25(3):306-12. PubMed ID: 12135102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
